Clinical Trial

A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2025 (before its estimated June 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on GLP-1 receptor agonists (GLP-1RAs), with or without oral antidiabetic drugs (OADs).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-07.
Trial Details
NCT Number NCT07055386
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 90 participants
Start Date 2025-08-07
Primary Completion 2026-06-28 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-21